Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
September 08, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
August 24, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp...
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) submission for tebentafusp in metastatic uveal melanoma...
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:05 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
Immunocore to present at upcoming investor conferences
May 27, 2021 16:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
May 18, 2021 16:10 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B IMC-I109V studied for the treatment of non-cirrhotic HBeAg-negative chronic...
Immunocore Reports First Quarter 2021 Financial Results
May 12, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2021 16:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Overall survival benefit from tebentafusp in patients with best...
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
April 12, 2021 16:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual...
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
March 25, 2021 07:00 ET
|
Immunocore Holdings Limited
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal...